Real-world clinical outcomes of treatment with brodalumab in patients with moderate-to-severe psoriasis: a retrospective, 24-month experience from four academic dermatology centers in Greece

References

• European Medicines Agency. Summary of product characteristics: Kyntheum 210 mg solution for injection in pre-filled syringe2017. Available from: https://www.ema.europa.eu/en/documents/product-information/kyntheum-epar-product-information_en.pdf.
   Google Scholar
• Blauvelt A, Papp KA, Lebwohl MG, et al. Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: a pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). J Am Acad Dermatol. 2017;77(2):372–374.
   PubMed Web of Science ®Google Scholar
• Papp KA, Lebwohl MG. Onset of action of biologics in patients With moderate-to-Severe psoriasis. J Drugs Dermatol. 2018;17(3):247–250.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Girolomoni G. Brodalumab in the treatment of chronic plaque psoriasis. Expert Opin Biol Ther. 2020;20(10):1175–1186.
   PubMed Web of Science ®Google Scholar
• Papp KA, Gordon KB, Langley RG, et al. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018;179:320–328.
   PubMed Web of Science ®Google Scholar
• Kimmel G, Chima M, Kim HJ, et al. Brodalumab in the treatment of moderate-to-severe psoriasis in patients who have previously failed treatment with antiinterleukin-17A therapies. J Am Acad Dermatol. 2019;81(3):857–859.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328.
   PubMed Web of Science ®Google Scholar
• Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–286.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Blauvelt A, Menter A, et al. Efficacy, safety, and patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with brodalumab for 5 years in a long-term, open-label, phase II study. Am J Clin Dermatol. 2019;20(6):863–871.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology life quality index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216.
   PubMed Web of Science ®Google Scholar
• van den Reek JMPA, Kievit W, Gniadecki R, et al. Drug survival studies in dermatology: principles, purposes, and pitfalls. J Invest Dermatol. 2015;135(7):1–5. ):
   PubMed Web of Science ®Google Scholar
• Samoutis A, Kaitelidou D, Siskou O. Moderate and severe plaque psoriasis: a quality of life and cost-of-illness study from Greece. Intl J Caring Sci. 2012;5:2.
   Google Scholar
• Rigopoulos D, Gregoriou S, Katrinaki A, et al. Characteristics of psoriasis in Greece: an epidemiological study of a population in a sunny mediterranean climate. Eur J Dermatol. 2010;20(2):189–195.
   PubMed Web of Science ®Google Scholar
• Ioannides D, Rigopoulos D, Delli F, et al. Effectiveness of brodalumab in patients with moderate-to-severe plaque psoriasis in the Greek clinical setting: results from an interim analysis of the BrIDGE study. 2021. DOI:10.13140/RG.2.2.20715.87844
   Google Scholar
• Tampouratzi E, Papakonstantis M, Katsantonis J, et al. Clinical evidence on the use of brodalumab for the treatment of psoriasis in Greece: experience from clinical practice of 4 tertiary hospitals. Dermatol Ther. 2022;35(7):e15532.
   PubMedGoogle Scholar
• Papadavid E, Katsimbri P, Kapniari I, et al. Prevalence of psoriatic arthritis and its correlates among patients with psoriasis in Greece: results from a large retrospective study. J Eur Acad Dermatol Venereol. 2016;30(10):1749–1752.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Caldarola G, De Simone C, et al. Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy. Expert Opin Biol Ther. 2021;21(9):1299–1310.
   PubMed Web of Science ®Google Scholar
• Garcia-Diez A, Foraster CF, Sebastian FV, et al. What characterizes the severity of psoriasis? Results from an epidemiological study of over 3,300 patients in the iberian region. Dermatology. 2008;216(2):137–151.
   PubMed Web of Science ®Google Scholar
• Fargnoli MC, Esposito M, Dapavo P, BRILLIANT Working Group, et al. Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience. J Eur Acad Dermatol Venereol. 2021;35(3):693–700.
   PubMed Web of Science ®Google Scholar
• Megna M, Ocampo-Garza SS, Potestio L, et al. New-onset psoriatic arthritis under biologics in psoriasis patients: an increasing challenge? Biomedicines. 2021;9(10):1482.
   PubMed Web of Science ®Google Scholar
• Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–390.
   PubMed Web of Science ®Google Scholar
• Imafuku S, Ohata C, Okubo Y, et al. Effectiveness of brodalumab in achieving treatment satisfaction for patients with plaque psoriasis: the ProLOGUE study. J Dermatol Sci. 2022;105(3):176–184.
   PubMed Web of Science ®Google Scholar
• Rasmussen L, Pratt N, Hansen MR, et al. Using the "proportion of patients covered" and the Kaplan-Meier survival analysis to describe treatment persistence. Pharmacoepidemiol Drug Saf. 2018;27(8):867–871.
   PubMed Web of Science ®Google Scholar
• Menditto E, Cahir C, Malo S, et al. Persistence as a robust indicator of medication adherence-related quality and performance. IJERPH. 2021;18(9):4872.
   Google Scholar
• Kojanova M, Hugo J, Velackova B, et al. Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry [published online ahead of print, 2022 may 29]. J Dermatolog Treat. 2022:1–11.
   PubMed Web of Science ®Google Scholar